KalVista Pharmaceuticals, Inc. Net Income Loss

• KalVista Pharmaceuticals, Inc. showed a decrease of -44.9% in Net Income Loss from 2024 to 2025.
• This data is from KalVista Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on July 10, 2025.
• XBRL data for this metric is available from 2013 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 14 years of available data (2013 to 2025), KalVista Pharmaceuticals, Inc.'s Net Income Loss has declined by 3,130.8%.
• Historical annual values: Fiscal year 2025: -$183.44 million | Fiscal year 2024: -$126.64 million | Fiscal year 2023: -$92.91 million | Fiscal year 2022: -$82.34 million | Fiscal year 2021: -$46.24 million | Fiscal year 2020: -$29.12 million | Fiscal year 2019: -$20.82 million | Fiscal year 2018: -$15.81 million | Fiscal year 2017: -$18.60 million | Fiscal year 2016: -$11.44 million | Fiscal year 2015: -$24.85 million | Fiscal year 2015: -$7.23 million | Fiscal year 2014: -$13.36 million | Fiscal year 2013: -$5.68 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026